Dr. Raymond Thertulien M.D.
Hematologist-Oncologist | Hematology & Oncology
20 Medical Park Dr Asheville NC, 28803About
Dr. Raymond Thertulien is a hematologist oncologist practicing in Asheville, NC. Dr. Thertulien specializes in the diagnosis, treatment and prevention of blood diseases such as anemia, hemophilia, sickle-cell disease, leukemia and lymphoma. Hematologist Oncologists are also trained in the study of cancer and its attack on other organs.
Provider Details
Clinical Trials
- Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
- Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Breast Cancer WEight Loss Study (BWEL Study)
- Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery
- S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
- Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
- Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
- S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer
- Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
- Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
- PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
- Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
- Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
- Cabozantinib S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
- Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
- Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
- Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Dr. Raymond Thertulien M.D.'s Practice location
CHARLOTTE, NC 28204Get Direction
Dr. Raymond Thertulien M.D.'s reviews
Write ReviewPatient Experience with Dr. Thertulien
Recommended Articles
- Microsoft Co-Founder Paul Allen Beats Lymphoma Twice
Beating any type of cancer is a major feat in itself, but billionaire and Microsoft co-founder Paul Allen has defeated lymphoma not once, but twice.Paul's storyNeedless to say, being the co-founder of Microsoft is a pretty big deal. As an American digital pioneer, Paul has been on top of the world....
- Treatments for Multiple Myeloma
The cancer care crew discusses what treatment will suit you after multiple myeloma has been diagnosed and staged. The following are treatments used in multiple myeloma:...
- What Are Lymphocytes?
A lymphocyte is a type of white blood cell (WBC) that has a significant function in the body's immune system. Lymphocytes function by properly responding to infectious microorganisms and other foreign invaders in the body. Lymphocytes can work alone, but some of them are also capable of...
- Astonishing Clinical Trial Results Show Promise for Non-Hodgkin Lymphoma Research
There’s good news for those who’ve been diagnosed with the aggressive non-Hodgkin lymphoma (NHL) type referred to as diffuse large-B cell (DLBCL). According to the American Cancer Society (ACS), this type of HNL is the most common type of lymphoma.The descriptive letters clarify the type of...
- Teen with Hodgkin Lymphoma Skates with Her Hero, Mario Lemieux
Lillian Tarasiewicz was diagnosed with stage 3B Hodgkin lymphoma in October of 2015. She currently resides in South Carolina, but because of her father’s Pennsylvania background, she grew up with a love for hockey and for the Pittsburgh Penguins. She always felt a special connection to Mario...
- Breaking News on the Treatment of Follicular Lymphoma
Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...
Nearby Providers
- Dr. Martin Palmeri M.D.,M.B.A.21 HOSPITAL DR Asheville NC 28801
- Dr. Michael Joseph Messino M.D.445 Biltmore Ave Asheville NC 28801
- Dr. Shonda Michelle Asaad M.D.20 Medical Park Dr. Asheville NC 28803
- Dr. Mohan Chand Thakuri MD445 Biltmore Ave Asheville NC 28801
- Dr. Louay Hanna M.D.20 Medical Park Drive Asheville NC 28803
- Dr. William M Butler MD80 DOCTORS DR STE 1 HENDERSONVILLE NC 28792